Our Story

In 2015, a team of leading cancer biology and immunology researchers at Stanford University partnered with experts in drug development, production and distribution, along with leading venture capital firms to found Forty Seven Inc. Our goal is to leverage its scientific founders’ professional experience and develop novel therapies that activate the immune system to help patients defeat their cancer. Over the past decade, our scientists have discovered that the first macrophage checkpoint —the CD47-SIRPɑ pathway—is an important mechanism for cancer immune evasion. Based on this pioneering discovery, Forty Seven Inc. became the first to develop and test a novel antibody against CD47 in clinical trials. We are committed to using our expertise to bring our CD47 antibody (and other novel therapies) to the clinic so that patients and their families will be able to access treatments that will aim to be instrumental in helping them beat their cancer.